1.
Correlation of CTCs in pre-treatment patients with clinical characteristics (N=31)
| Variables | Cases No. | CTC number (per 7.5 mL) [n (%)] | ||||
| ≥1 | ≥2 | ≥3 | ≥4 | ≥5 | ||
| CTCs, circulating tumor cells; HER2, human epidermal growth factor receptor 2; *, two patients had unavailable HER2 status information. | ||||||
| Total | 31 | 29 (93.5) | 24 (77.4) | 18 (58.1) | 15 (48.4) | 14 (45.2) |
| Gender | ||||||
| Female | 10 | 9 (90.0) | 9 (90.0) | 6 (60.0) | 6 (60.0) | 6 (60.0) |
| Male | 21 | 20 (95.2) | 15 (71.4) | 12 (57.1) | 9 (42.9) | 8 (38.1) |
| P | 0.548 | 0.251 | 0.579 | 0.306 | 0.224 | |
| Age (year) | ||||||
| ≥60 | 19 | 18 (94.7) | 14 (73.7) | 12 (63.2) | 11 (57.9) | 10 (52.6) |
| <60 | 12 | 11 (91.7) | 10 (83.3) | 6 (50.0) | 4 (33.3) | 4 (33.3) |
| P | 0.632 | 0.435 | 0.362 | 0.168 | 0.249 | |
| Primary tumor site | ||||||
| Stomach | 18 | 17 (94.4) | 13 (72.2) | 9 (50.0) | 8 (44.4) | 7 (38.9) |
| Gastroesophageal junction | 13 | 12 (92.3) | 11 (84.6) | 9 (69.2) | 7 (53.8) | 7 (53.8) |
| P | 0.671 | 0.358 | 0.242 | 0.439 | 0.323 | |
| Lauren classification | ||||||
| Intestinal | 18 | 17 (94.4) | 15 (83.3) | 12 (66.7) | 9 (50.0) | 9 (50.0) |
| Diffuse | 6 | 5 (83.3) | 2 (33.3) | 2 (33.3) | 2 (33.3) | 2 (33.3) |
| Mixed | 7 | 7 (100) | 7 (100) | 4 (57.1) | 4 (57.1) | 3 (42.9) |
| P | 0.427 | 0.010 | 0.358 | 0.673 | 0.657 | |
| Sites of metastasis | ||||||
| Liver | ||||||
| Yes | 10 | 9 (90.0) | 7 (70.0) | 6 (60.0) | 4 (40.0) | 4 (40.0) |
| No | 21 | 20 (95.2) | 17 (81.0) | 12 (57.1) | 11 (52.4) | 10 (47.6) |
| P | 0.548 | 0.401 | 0.597 | 0.398 | 0.497 | |
| Peritoneum | ||||||
| Yes | 5 | 5 (100) | 4 (80.0) | 2 (40.0) | 1 (20.0) | 1 (20.0) |
| No | 26 | 21 (80.8) | 20 (76.9) | 16 (61.5) | 14 (53.8) | 13 (50.0) |
| P | 0.699 | 0.688 | 0.341 | 0.186 | 0.233 | |
| HER2 status* | ||||||
| Positive | 13 | 12 (92.3) | 10 (76.9) | 8 (61.5) | 6 (46.2) | 5 (38.5) |
| Negative | 16 | 15 (93.8) | 12 (75.0) | 9 (56.3) | 8 (50.0) | 8 (50.0) |
| P | 0.727 | 0.583 | 0.714 | 0.978 | 0.816 | |